Annual report [Section 13 and 15(d), not S-K Item 405]

Cover page

v3.25.4
Cover page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Feb. 25, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2025    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 000-29889    
Entity Registrant Name RIGEL PHARMACEUTICALS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 94-3248524    
Entity Address, Address Line One 611 Gateway Boulevard, Suite 900,    
Entity Address, City or Town South San Francisco    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94080    
City Area Code 650    
Local Phone Number 624-1100    
Title of 12(b) Security Common Stock, par value $.001 per share    
Trading Symbol RIGL    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 331.6
Entity Common Stock, Shares Outstanding   18,473,130  
Documents Incorporated by Reference
Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K incorporate information by reference from the definitive proxy statement for the registrant’s 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission (SEC) pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.
   
Entity Central Index Key 0001034842    
Document Fiscal Period Focus FY    
Amendment Flag false    
Document Fiscal Year Focus 2025